Market Closed -
Japan Exchange
02:00:00 2024-06-27 EDT
5-day change
1st Jan Change
5,640
JPY
+1.26%
+3.11%
+9.73%
Noevir : Results for the First Half of Fiscal 2024
Noevir Holdings Co., Ltd.
Results for the First Half of Fiscal 2024
(October 1, 2023 - March 31, 2024)
May 16, 2024
Noevir Holdings Co., Ltd.
Ikkou Yoshida, Managing Director
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Company Overview
Noevir Holdings Co., Ltd. Tokyo Stock Exchange, Prime Market Ticker: 4928
Date of Establishment
March 22, 2011 (Noevir Co., Ltd. was founded in April 1964.)
Paid-in Capital
¥7,319 million
Consolidated Subsidiaries
13 subsidiaries (6 domestic / 7 international)
Employees
1,368 (Consolidated) (As of September 30, 2023)
Number of Shareholders
19,663 (As of March 31, 2024)
Outstanding Shares
34,156 thousand shares
Market Capitalization
¥181.030 billion (May 15, 2024 @ ¥5,300)
Line of Business
Cosmetics
Pharmaceuticals & Health Food
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Apparel
business Aviation- related business
Other
1. Results for the First Half of Fiscal 2024
2. The First Half of Fiscal 2024 Segment-Based Highlights
3. Medium-term Management Plan
4. Forecasts and Initiatives
for the Second Half of Fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024
Consolidated Results Summary
Increased sales and profits vs. actual results year on year
1st half of
Year-on-year
fiscal 2024
change
Net sales
31.6 billion yen
+2.4
Operating income
6.1 billion yen
+7.2
Operating income margin
19.5
+0.9pt
➢ Factors increasing sales and profits
Operating income
(1) Self-selection cosmetics performed strongly
margin
19.5
(2) SG&A expenses were streamlined
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024 Highlights
Net sales 31.6 billion yen (+2.4% year-on-year), operating income 6.1 billion yen (+7.2%),
ordinary income 6.2 billion yen (+7.5%), net income attributable to owners of the parent 2.5 billion yen (-2.8%)
1st half ended
1st half ended
Year-on-year change
March 31, 2024
March 31, 2023
Millions of yen
Millions of yen
Millions of yen
Cost of sales
9,935
9,629
306
3.2
Gross profit
21,689
21,267
422
2.0
SG&A
15,524
15,517
7
0.0
Operating income
6,165
5,750
415
7.2
Non-operating income (expenses)
80
59
21
36.5
Ordinary income
6,246
5,809
436
7.5
Extraordinary income (loss)
13
(1)
15
Income before income taxes
6,259
5,807
451
7.8
Income taxes
3,661
3,135
526
16.8
Net income attributable to owners of the parent
2,597
2,672
(74)
(2.8)
Cost of sales ratio (%)
31.4
31.2
0.2pt
Operating income margin (%)
19.5
18.6
0.9pt
Ordinary income margin (%)
19.8
18.8
0.9pt
Net income attributable to owners of the parent margin (%)
8.2
8.6
(0.4pt)
SG&A ratio (%)
49.1
50.2
(1.1pt)
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Operating Income Margin
18.3%
16.7%17.6%
FY2014
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
1st half of
fiscal 2024
Continued to maintain a high operating income margin in 1H FY2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024
Reasons for Change in Operating Income
+422
+24
Increasein gross profit
salestodue increase
-31
5,750
Increase in A&P
Decreasein sundry expenses
1st half of
Increase in operating income of 415 million yen
fiscal 2023
(Millions of yen)
Factors increasing profit Factors decreasing profit
6,165
1st half of fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Monthly Net Sales in the
Cosmetics Segment Year on Year
Fiscal 2024
Oct.
Nov.
Dec.
Jan.
Feb.
Mar.
Apr.
May
Jun.
Jul.
Aug. Sep.
Oct.
Nov.
Dec.
Jan.
Feb. Mar.
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Results for the First Half of Fiscal 2024
The First Half of Fiscal 2024 Segment-Based Highlights
Medium-term Management Plan
Forecasts and Initiatives
for the Second Half of Fiscal 2024
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
The First Half of Fiscal 2024 Segment-Based Highlights
1st half ended
1st half ended
Year-on-year change
March 31, 2024
March 31, 2023
Millions of yen
Millions of yen
Millions of yen
Cosmetics
Net sales
25,103
24,091
1,011
4.2
Segment income
6,507
6,174
333
5.4
Pharmaceuticals &
Health Food
Net sales
5,498
5,579
(81)
(1.5)
Segment income
683
542
141
26.1
Other
Net sales
1,024
1,225
(201)
(16.4)
Segment income
150
164
(14)
(8.8)
Consolidated net
31,625
30,896
729
2.4
sales
Other
Pharmaceuticals &3.2 %
Health Food
17.4%
Net sales
31,625
million yen
Cosmetics
79.4%
Composition of net sales in the first half of fiscal 2024
Cosmetics
Pharmaceuticals &
Health Food
Other
Sales and profits increased year on year
Sales decreased and profits increased year on year
Sales and profits decreased year on year
Sales and profit increased due to firm sales of self-selection cosmetics
Profit increased due to improved cost efficiency, despite decreased sales of functional drinks
Sales decreased in aviation-related business
Copyright © 2024 Noevir Holdings Co., Ltd. All Rights Reserved.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Noevir Holdings Co. Ltd. published this content on
16 May 2024 and is solely responsible for the information contained therein. Distributed by
Public , unedited and unaltered, on
16 May 2024 00:05:01 UTC .
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024
11-07
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024
23-08-07
CI
Noevir Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023
23-05-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2023
23-05-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023
23-02-07
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending March 2023 and for the Fiscal Year Ending September 30, 2023
22-11-10
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022
22-08-04
CI
Noevir Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2022
22-05-11
CI
Noevir Holdings Co., Ltd. Provides Earnings Guidance for the Six Months Ending March 2022 and for the Year Ending September 2022
22-02-08
CI
FACTBOX-Japanese companies opening COVID-19 vaccination sites amid slow national rollout
21-06-04
RE
An unknown buyer acquired a 12.9% stake in Noevir Holdings Co., Ltd. from Takashi Okura.
20-08-02
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2019; Provides Earnings Guidance for the Fiscal Year Ending September 30, 2019
19-08-13
CI
Noevir Holdings Co., Ltd. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2018; Provides Earnings Forecast for the Half Year of the Fiscal Year Ending Sept. 30, 2019; Provides Earnings Forecast for the Full Year of the Fiscal Year Ending Sept. 30, 2019; Provides Dividend Forecast for the Fourth Quarter of Fiscal Year Ending Sept. 30, 2019
19-02-11
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Year Ended September 30, 2018; Provides Earnings Guidance for the Half Year and Year Ending September 30, 2019
18-11-19
CI
Noevir Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending September 30, 2018; Announces Consolidated Earnings Results for the Nine Months Ended June 30, 2018; Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2018
18-08-12
CI
Noevir Holdings Co., Ltd.(TSE:4928) added to FTSE All-World Index
18-03-19
CI
Noevir Holdings Co., Ltd.(TSE:4928) added to FTSE All-World Index
18-03-19
CI
Noevir Holdings Co., Ltd. Announces Unaudited Earnings Results for the Three Months Ended December 31, 2017; Provides Earnings Guidance for the Half Year and Full Year for the Fiscal Year Ended September 30, 2018
18-01-31
CI
Tranche Update on Noevir Holdings Co., Ltd.'s Equity Buyback Plan announced on November 7, 2017.
17-11-08
CI
Noevir Holdings Co., Ltd.'s Equity Buyback announced on November 7, 2017 has expired with 1,295,000 shares for ¥9,971.5 million.
17-11-08
CI
Noevir Holdings Co., Ltd. announces an Equity Buyback for 1,500,000 shares, representing 4.23% for ¥11,000 million.
17-11-07
CI
Noevir Holdings Co., Ltd. authorizes a Buyback Plan.
17-11-06
CI
Noevir Holdings Co., Ltd. Announces Consolidated Earnings Results for the Full Year Ended September 30, 2017; Provides Consolidated Earnings Guidance for the First Half and Full Year Ending September 30, 2018; Announces Year-End Dividend for the Year Ended September 30, 2017, Payable on December 8, 2017; Provides Dividend Guidance for the Year Ending September 30, 2018
17-11-06
CI
Noevir Holdings Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended June 30, 2017; Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2017
17-07-31
CI
Noevir Holdings Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2017
17-04-27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Noevir Holdings Co., Ltd. is a Japan-based company engaged in the manufacture and sale of cosmetics, toiletries, pharmaceuticals and foods, as well as the purchase and sale of cosmetic products. The Company operates in three business segments. The Cosmetics segment is engaged in the manufacture and sale of cosmetics and toiletries, as well as the purchase and sale of cosmetic products. The Pharmaceuticals and Foods segment is engaged in the manufacture and sale of general drugs and foods. The Others segment is engaged in the purchase and sale of apparels, body fashion, aircrafts and vessels, as well as air transportation business.
More about the company
Last Close Price
5,570
JPY
Average target price
5,730
JPY
Spread / Average Target
+2.87%
Consensus
1st Jan change
Capi.
+9.73% 1.18B 0.00% 20.28B +15.83% 19.69B +13.52% 12.04B -18.76% 8.71B +22.48% 7.82B +14.68% 6.19B -8.94% 3.87B +0.43% 3.8B -19.06% 3.73B
Cosmetics & Perfumes
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1